Clinical Characterization and Treatment Response of Folliculitis Decalvans Lichen Planopilaris Phenotypic Spectrum: A Unicentre Retrospective Series of 31 Patients

Ana MELIÁN-OLIVERA1,2, Óscar M. MORENO-ARRONES1,2, Patricia BURGOS-BLASCO1,2, Ángela HERMOSA-GELBARD1,2, Pedro JAÉN-OLASOLO1,2, Sergio VAÑÓ-GALVÁN1,2 and David SACEDA-CORRALO1,2

1Department of Dermatology, University Hospital Ramón y Cajal, Madrid, Spain and 2Trichology Unit, Grupo de Dermatología Pedro Jaén, Madrid, Spain

Folliculitis decalvans and lichen planopilaris phenotypic spectrum has been described as a form of cicatricial alopecia. The aim of this study is to describe the clinical and trichoscopic features and therapeutic management of this condition in a series of patients. A retrospective observational unicentre study was designed including patients with folliculitis decalvans and lichen planopilaris phenotypic spectrum confirmed with biopsies. A total of 31 patients (20 females) were included. The most common presentation was an isolated plaque of alopecia (61.3%) in the vertex. Trichoscopy revealed hair tufting with perifollicular white scaling in all cases. The duration of the condition was the only factor associated with large plaques (grade III) of alopecia (p = 0.026). The mean time to transition from the classic presentation of folliculitis decalvans to folliculitis decalvans and lichen planopilaris phenotypic spectrum was 5.2 years. The most frequently used treatments were topical steroids (80.6%), intralesional steroids (64.5%) and topical antibiotics (32.3%). Nine clinical relapses were detected after a mean time of 18 months (range 12–23 months). Folliculitis decalvans and lichen planopilaris phenotypic spectrum is an infrequent, but probably underdiagnosed, cicatricial alopecia. Treatment with anti-inflammatory drugs used for lichen planopilaris may be a suitable approach.

Key words: cicatricial alopecia; hair follicle; hair tufting; scarring hair loss; trichoscopy.

Submitted Apr 23, 2023. Accepted after review Jan 10, 2024

Published Feb 19, 2024. DOI: 10.2340/actadv.v104.12373
Acta Derm Venereol 2024; 104: adv12373.

Corr: Sergio Vañó-Galván, Department of Dermatology, University Hospital Ramón y Cajal, Madrid, Spain. Carretera Colmenar Viejo km 9.100, ES-28034 Madrid, Spain. E-mail: drsergiogovo@gmail.com

Occasionally, FD may share clinical and histological characteristics with lichen planopilaris (LPP) (5). It implies a significant diagnostic challenge and deserves a careful correlation between clinical, trichoscopic and histopathological features (6). Recent publications have described small case series of patients with this entity, and the term “FD and LPP phenotypic spectrum” (FDLPPPS) was proposed recently (7). However, the idea of spectrum of FD/LPP is still debatable and several authors consider that this clinical presentation may be the result of LPP-like changes in late FD (5).

The aim of this study was to describe the clinical and trichoscopic characteristics, and therapeutic management in a series of patients diagnosed with FDLPPPS.

MATERIALS AND METHODS

A retrospective study was designed including patients diagnosed with FD between 2010 and 2021 at the Trichology Unit in Hospital Ramon y Cajal, Madrid, Spain, who finally met criteria for FDLPPPS. To confirm the diagnosis of FDLPPPS it was necessary to have a well-recorded personal history of FD with histopathological confirmation in all cases and an objective change to LPP-like clinical features, according to Yip et al.’s criteria (5), and trichoscopic features.

Data were collected regarding epidemiology, clinical presentation (size, number, shape and location of alopecic patches, presence of pustules, yellow crusts, polytrichia and concomitant pityriasis amiantacea), time to FDLPPPS presentation since previous diagnosis of FD, symptoms, trichoscopic findings (hair tufting of 2–5
hairs or > 6 hairs, perifollicular erythema, perifollicular scaling, interfollicular scaling, follicular haemorrhages, white dots, vascular patterns and others) and therapeutic options.

Data relating to treatment (total of therapies used, treatments received 3 months before the first presentation of FDLPPPS clinical features, response to treatment and side-effects detected) and time to relapse were also analysed.

To stratify the severity of FDLPPPS, this study applied the same approach that was used for FD (3 grades according to the maximum diameter of the largest patch of alopecia; grade I: <2 cm, II: 2–4.99 cm, III: 5 cm or more) (8). The onset of FDLPPPS was considered when they showed clinical (and trichoscopic) features of this entity and no inflammatory flare-ups for a year. Relapses were considered in either 3 situations: progression of the alopecia was observed, clinical inflammatory flare-up (pustules, exudative crusts with or without symptoms) and trichoscopic features of activity (2 points or more in the FD Activity Scale) (2).

Statistical analysis
After data gathering statistical analysis was performed. For categorical variables, frequencies were reported. For continuous variables, mean and range were calculated. The relationship between epidemiological, clinical and trichoscopic features and severity groups was analysed. To assess the statistical significance of differences observed between groups, we performed an univariate analysis using the χ2 and Mann–Whitney U tests for categorical and continuous variables, respectively. All tests were 2-sided and statistical significance was considered with p < 0.05. For all statistical analyses, the statistical software package SPSS (Version 25.0. Armonk, NY: IBM Corp) was used.

RESULTS
A total of 31 Caucasian patients (20 females and 11 males) with a median age of 40 years (range 23–66 years) were recruited. None of the patients had a family history of FD or LPP. The median age of onset of the condition was 34 years (range 22–51 years). The associated dermatological comorbidities were: androgenetic alopecia (17 patients, 54.8%), seborrhoeic dermatitis on the scalp (9 patients, 29.0%), atopic dermatitis in 2 patients and vulvar lichen sclerosus in 1 patient.

Clinically, 19 patients (61.3%) presented a unique plaque of alopecia on the scalp and 12 patients (38.7%) had 2 or more areas affected (Fig. 1). The most common location was the vertex (in 27 patients, 87.1%), followed by parietal area (12 patients, 38.7%), occipital area (5 patients, 16.1%) and the frontal area (2 patients, 6.5%). The mean size of the area affected was 20.6 cm² (range 1–187 cm²). Three patients (9.7%) had a grade I extension of alopecia, 11 patients (35.5%) grade II, and 17 patients (54.8%) grade-III. An oval or round shape was the most frequent clinical presentation (18 patients, 58.1%), followed by diffuse hair loss in 8 patients (25.8%), a multifocal patchy hair loss in 3 patients and a large wedge-shaped plaque of alopecia in 2 patients. At the time of the shift to LPP-like features, all patients presented polytrichia, 7 patients associated isolated clinical characteristics of FD (6 patients had yellowish crusts and 1 patient follicular pustules) and 4 patients had concomitant pityriasis amiantacea. Pruritus was referred by 14 patients (45.2%) and trichodynia by 3 patients (9.7%).

Trichoscopy revealed hair tufting and perifollicular white scaling in all cases (Fig. 2) (the remaining trichoscopic features are summarized in Table 1).

After statistical analysis, the duration of the condition was the only factor associated with grade III forms of FDLPPPS (p = 0.026). The presence of white dots on trichoscopy was higher in grade I–II cases than in severe forms of the disease (p = 0.015). No other clinical factors were correlated with the severity of the disease.

Once the diagnosis of FDLPPPS was established, the patients were followed for a mean of 2.9 years (range 1–9 years). A total of 18 patients (58.1%) changed over to the FDLPPPS spectrum during the follow-up in our department, and 13 patients (41.9%) had received a previous diagnosis of FD in another dermatological centre. The mean time since the first diagnosis of FD was 5.2 years (range 1–22 years). Treatments used before and

![Image](image-url)

**Fig. 1.** Clinical presentation of folliculitis decalvans and lichen planopilaris phenotypic spectrum. A unique cicatricial plaque of alopecia with hair tufts of 6 or more hair follicles.

Table 1. Trichoscopic features of patients with folliculitis decalvans and lichen planopilaris phenotypic spectrum

<table>
<thead>
<tr>
<th>Trichoscopic sign</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hair shaft alterations</td>
<td></td>
</tr>
<tr>
<td>Hair tufting</td>
<td></td>
</tr>
<tr>
<td>• tufts ≥ 6 hairs</td>
<td>31 (100)</td>
</tr>
<tr>
<td>• tufts 2–5 hairs</td>
<td>18 (58.1)</td>
</tr>
<tr>
<td>Perifollicular structures</td>
<td></td>
</tr>
<tr>
<td>Perifollicular white scaling</td>
<td>31 (100)</td>
</tr>
<tr>
<td>Perifollicular erythema</td>
<td>25 (80.6)</td>
</tr>
<tr>
<td>Perifollicular yellow scales</td>
<td>6 (19.4)</td>
</tr>
<tr>
<td>Follicular pustules</td>
<td>6 (19.4)</td>
</tr>
<tr>
<td>Follicular haemorrhages</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Interfollicular structures</td>
<td></td>
</tr>
<tr>
<td>Milky-red areas</td>
<td>15 (48.4)</td>
</tr>
<tr>
<td>Interfollicular scaling</td>
<td>7 (22.6)</td>
</tr>
<tr>
<td>In-growing hairs</td>
<td>4 (12.9)</td>
</tr>
<tr>
<td>Yellow structureless areas</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Vascular structures</td>
<td></td>
</tr>
<tr>
<td>Linear vessels</td>
<td>10 (32.3)</td>
</tr>
<tr>
<td>Thin arborizing vessels</td>
<td>8 (25.8)</td>
</tr>
<tr>
<td>Thick arborizing vessels</td>
<td>4 (12.9)</td>
</tr>
<tr>
<td>Thick-root vessels</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Diffuse vascular network</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Total</td>
<td>31 (100)</td>
</tr>
</tbody>
</table>
after the first presentation of FDLPPPS spectrum and during it are shown in Table SI. In 1 patient, no treatment was started, as he referred stabilization of his alopecia for 2 years. The side-effects recorded were 2 cases of gastrointestinal discomfort due to oral doxycycline and 5 cases with temporary scalp atrophy due to intralesional steroids. None of the side-effects was severe enough to discontinue treatment.

A total of 9 relapses of FDLPPPS were detected in 8 patients (25.8%) during follow-up. All of these patients presented inflammatory clinical signs in isolated areas of the alopecia plaque, except for 1 patient who had a generalized FD flare-up. The flare-ups took place after a mean time of 18 months (range 12–23 months) since FDLPPPS diagnosis. Four of those relapses occurred after an interruption of the medical treatment (all of them only with topical treatment) for a mean time of 8 months due to the SARS-CoV-2 (COVID-19) pandemic. The treatments that patients were receiving before the flare-up, and to treat the flare-up, are shown in Fig. 3.

**DISCUSSION**

As highlighted in previous studies, FDLPPPS is a not uncommon presentation for dermatologists specializing in conditions affecting the hair. Trüeb et al. (9) were the first to report on the bi-phasic nature of FD based on their sequential dermoscopic observations in FD. Yip et al. (5) described this clinical presentation in 13 patients for the first time in 2019, Egger et al. (7) studied 7 patients shortly after, and Müller-Ramos et al. (10)

![Fig. 2. Trichoscopy of folliculitis decalvans and lichen planopilaris phenotypic spectrum. Loss of follicular openings and hair tufting. White perifollicular scales and ingrowing hairs are visible. [AQ5]](image)

![Fig. 3. Treatments received by patients before and during the flare-up. HXQ: hydroxychloroquine; DXM: dexamethasone; bid: twice a day. †All patients also received intralesional steroids. ‡Four patients discontinued medical treatment due to the SARS-CoV-2 (COVID-19) pandemic. §One patient experienced 2 relapses.](image)
described 2 paediatric cases. However, some case reports describing patients with clinical overlap between LPP and FD (11–13) suggest that clinicians might encounter FDLPPPS cases more often than currently believed. To our knowledge, this study describes the largest series of FDLPPPS in the literature to date.

Regarding clinical features, the most common presentation of FDLPPPS was a single plaque on the vertex, a finding also observed in previous studies. The presence of a single cicatricial patch on the vertex with trichoscopic signs of LPP and hair tufting of 6 or more hair shafts should raise the suspicion of a FDLPPPS diagnosis. According to the severity-scale of FD, most of the cases of FDLPPPS included in this study were grade III. Both characteristics support the hypothesis that most of the cases of FDLPPPS are presentations of long-term FD in chronic stages. In fact, this “LPP-like” clinical presentation is rather a manifestation of a final common pathway seen in diverse scarring alopecias, including FD (5). It is important to take this into account, to avoid misdiagnosis and therapeutic errors by confusion with primary LPP, whose immunological differences have been demonstrated (14). As Trüeb et al. (9) proposed, the development of features of LPP with time may be due to the disruption of hair follicles in the course of the bacterial infection, with consecutive exposure of follicular antigens ultimately giving rise to autoimmunity targeting the hair follicle at critical sites. In addition, there are other clinical presentations that are different in distribution (multifocal or diffuse) and location (parietal or occipital area). These situations may reflect a disruption of the follicular immune-privilege on the whole scalp, that it has been also demonstrated in other cicatricial alopecias (15, 16).

The scarce symptoms associated with this condition are also notable. Pruritus was found in less than the half of our patients and trichodynia in only 3 cases. This is much less frequent than symptoms associated with FD (68% of the patients have associated pruritus and 30% trichodynia).

The use of oral antibiotics in FD is controversial due to increasing antibiotic resistance (17); in our series, most of the patients were taking oral doxycycline or the combination of oral clindamycin and rifampicin. Both options have demonstrated to induce a significant improvement in FD during 4.8–7.2 months, respectively (8, 18). Oral antibiotics could be necessary to induce a prolonged remission in acute stages of FD that, at some point, is followed by a definitive change to the chronic lichenoid stages of FDLPPPS.

The treatment may be different once the FDLPPPS is established. Recent investigations have shown that the role of *Staphylococcus aureus* might be less relevant in FDLPPPS forms, and anti-inflammatory treatments should be prioritized (19). In the current study, the options most used were topical and intralesional steroids, followed by topical antibiotics. The oral treatment is not well defined, but immunomodulatory therapeutic options are used more often (e.g. oral isotretinoin, hydroxychloroquine, dexamethasone and cyclosporine). In our experience, FDLPPPS is easier to control than the FD or the LPP classical forms, which means a better prognosis for patients in this stage. The authors propose a therapeutic approach in Fig. 4 that combines those used in FD and classic LPP, based on the degree of inflammatory activity and the course of alopecia. The low number of cases of reactivation of FD do not allow further analysis. However, the treatment in those

![Fig. 4. Proposal of therapeutic algorithm for folliculitis decalvans and lichen planopilaris phenotypic spectrum (FDLPPPS). This therapeutic algorithm is a proposal by the authors.](image)
patients was almost stopped and totally interrupted in 4 cases.

Limitations
This study has some limitations. First, the retrospective design of the study might entail loss of some relevant data. It is likely that some patients were missed, who had visited our department during the previous decade, as there was no knowledge about this clinical presentation. Secondly, it was not possible to assess the efficacy of the treatment in stopping the progression of the alopecia. However, it was possible to identify information useful for clinicians, such as the therapeutic approaches used in clinical practice that might avoid new inflammatory outbreaks.

Conclusion
FDLPPPS is a rare, but probably underdiagnosed, presentation of cicatricial alopecia that should be suspected in patients with long-standing classical FD with clinical and trichoscopic changes to LPP, or in patients with concomitant features of both entities. Most of the cases in the current study were the result of chronic FD after several courses of medical therapies, frequently with oral antibiotics. The treatment is not well defined, but the use of therapies for classical LPP seems to be an adequate approach.

ACKNOWLEDGEMENTS
Alberto Ramírez-Follarat, MD, Psychologist, Department of Dermatology, University Hospital Ramón y Cajal, Madrid, Spain.

This research has been approved by Institutional Review Board IRYCIS at Ramón y Cajal Hospital, in Madrid (ID CI-BIOB-037-01). The patients in this manuscript have given written informed consent to publication of their case details.

The authors have no conflicts of interest to declare.

REFERENCES
6. Matard B, Cavelier-Balloy B, Assouly P, Reygagne P. It has the erythema of a lichen planopilaris, it has the hyperkeratosis of a lichen planopilaris, but it is not a lichen planopilaris: about the “lichen planopilaris-like” form of folliculitis decalvans. Am J Dermatopathol 2021; 43: 235–236.